PDCD1 and neoplasm: Since anti-CTLA-4 could restrict tumor-induced neutrophil accumulation, an anti-PD-1 + anti-CTLA-4 combination overcomes anti-PD-1 resistance in hosts with MSI-H tumors displaying abnormal neutrophil infiltration.